Aggrecan G1-IGD-G2 Domains Protein 1220-PG-025 from R&D Systems, a Bio-Techne Brand

Product Specs
ItemAggrecan G1-IGD-G2 Domains Protein
CompanyR&D Systems, a Bio-Techne Brand
Price $576.00Supplier Page View Company Product Page
Catalog Number1220-PG-025
FormatLyophilized from a 0.2 µm filtered solution in Tris and NaCl
SpeciesHuman
Molecule NameAggrecan
Size25 ug
NCBI Full Gene Nameaggrecan
NCBI Gene AliasesCSPG1, SSOAOD, CSPGCP, MSK16, AGC1, AGCAN, SEDK
Purity>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining
ApplicationsEnzyme Activity, Binding Activity
Conjugate/TagUnconjugated
Source/Expression SystemNS0-derived Recombinant Human Aggrecan G1-IGD-G2 Domains Protein, CF
StorageUse a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution

Available conjugates: Sizes Available: 25 ug

614 McKinley Place N.E.

Minneapolis, Minnesota 55413

United States

Phone: 1 (800) 343-7475
1 (612) 379-2956

Fax: 1 (612) 656-4400

(1) Inhibition of fibroblast activation protein ameliorates cartilage matrix degradation and osteoarthritis progressionBone researchJanuary 2, 2023Fan A, Wu G, Wang J, Lu L, Wang J, Wei H, Sun Y, Xu Y, Mo C, Zhang X, et al.or denatured (heated at 95 °C for 10 min) recombinant human Aggrecan (G1-IGD-G2 domain, R&D Systems, 1220-PG-025) were incubated in 10 μL PBS buffer at 37 °C for 24 h. Enzymatic reactions were stopped by adding loading

(3) Parvalbumin interneuron-derived tissue-type plasminogen activator shapes perineuronal net structureBMC biologyOctober 5, 2022Lépine M, Douceau S, Devienne G, Prunotto P, Lenoir S, Regnauld C, Pouettre E, Piquet J, Lebouvier L, Hommet Y, et al.

(6) Increased matrix metalloproteinase levels and perineuronal net proteolysis in the HIV-infected brain; relevance to altered neuronal population dynamicsExperimental neurologyJanuary 1, 2020Bozzelli PL, Caccavano A, Avdoshina V, Mocchetti I, Wu JY, Conant K.BML-SE246-0010) was used at a concentration of 17.5 μg/mL. Recombinant human aggrecan (R&D, catalog # 1220-PG-025) was used at a concentration of 62.5 μg/mL and recombinant human brevican (R&D, catalog # 5800-NC-050)

(8) The serine proteinase hepsin is an activator of pro-matrix metalloproteinases: molecular mechanisms and implications for extracellular matrix turnoverScientific reportsDecember 1, 2017Wilkinson DJ, Desilets A, Lin H, Charlton S, Del Carmen Arques M, Falconer A, Bullock C, Hsu YC, Birchall K, Hawkins A, et al.

(9) Identification of a novel HtrA1-susceptible cleavage site in human aggrecan: evidence for the involvement of HtrA1 in aggrecan proteolysis in vivoThe Journal of biological chemistryOctober 2, 2009Chamberland A, Wang E, Jones AR, Collins-Racie LA, LaVallie ER, Huang Y, Liu L, Morris EA, Flannery CR, Yang Z.

Aggrecan G1-IGD-G2 Domains Protein from R&D Systems, a Bio-Techne Brand